LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MET exon 14 skipping is a known driver of cancer, leading to sustained oncogenic signaling and sensitivity to targeted therapies.
• This event typically arises from small mutations near splice sites.
• The role of larger genetic elements in causing this specific mutation has been unclear.

Purpose of the Study:

• To investigate novel mechanisms causing MET exon 14 skipping.
• To identify the role of long interspersed element-1 (LINE-1) retrotransposition in generating these mutations.
• To characterize the clinical actionability of these newly identified mutations.

Main Methods:

• Analysis of tumor genomic data to identify insertions within or near MET exon 14.
• Characterization of insertion sequences, including LINE-1 elements and pseudogene insertions.
• Correlation of identified mutations with clinical data and patient response to MET tyrosine kinase inhibitors.

Main Results:

• Nine cases of MET exon 14 skipping were attributed to LINE-1 mediated insertions.
• One case involved a LINE-1 mediated pseudogene insertion.
• These findings represent the first recurrent, clinically actionable mutations caused by LINE-1 retrotransposition in cancer.

Conclusions:

• LINE-1 retrotransposition is a newly identified mechanism for generating pathogenic MET exon 14 skipping mutations.
• These mutations are clinically actionable, offering new therapeutic targets.
• This discovery expands our understanding of the mutational landscape in cancer.